These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28462402)

  • 1. Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT.
    Ebrahimi M; Akbari-Asbagh F; Ghalandar-Attar M
    Int J Reprod Biomed; 2017 Feb; 15(2):101-108. PubMed ID: 28462402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letrozole as co-treatment agent in ovarian stimulation antagonist protocol in poor responders: A double-blind randomized clinical trial.
    Moini A; Lavasani Z; Kashani L; Mojtahedi MF; Yamini N
    Int J Reprod Biomed; 2019 Sep; 17(9):653-660. PubMed ID: 31646260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
    Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
    Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysis.
    Qin Y
    J Gynecol Obstet Hum Reprod; 2021 Oct; 50(8):102139. PubMed ID: 33838300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
    Olgan S; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Stimulation Protocol for Poor-Responder Patients: Combining the Stop GnRH-ag Protocol with Letrozole Priming and Multiple-Dose GnRH-ant: A Proof of Concept.
    Orvieto R; Nahum R; Aizer A; Haas J; Kirshenbaum M
    Gynecol Obstet Invest; 2021; 86(1-2):149-154. PubMed ID: 33761501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization.
    Lee KH; Kim CH; Suk HJ; Lee YJ; Kwon SK; Kim SH; Chae HD; Kang BM
    Obstet Gynecol Sci; 2014 May; 57(3):216-22. PubMed ID: 24883293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
    Cheng ZX; Kong G; Zhang CL; Zhao YN
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients.
    Ozcan Cenksoy P; Ficicioglu C; Kizilkale O; Suhha Bostanci M; Bakacak M; Yesiladali M; Kaspar C
    Gynecol Endocrinol; 2014 Jul; 30(7):485-9. PubMed ID: 24592985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.